Business Standard

Pfizer Covid-19 jab produces less antibodies against Delta variant: Lancet

The study also shows that levels of these antibodies that are able to recognise and fight the virus are lower with increasing age

Pfizer Vaccine, Coronavirus vaccine
Premium

Data from previous clinical studies suggests that higher antibody titres or concentration is a good predictor of vaccine efficacy

Press Trust of India London
People fully vaccinated with the Pfizer-BioNTech vaccine are likely to have more than five times lower levels of neutralising antibodies against the Delta variant first identified in India compared to the original strain, according to research published in The Lancet journal.
 
The study also shows that levels of these antibodies that are able to recognise and fight the virus are lower with increasing age, and that levels decline over time, providing additional evidence in support of plans to deliver a booster dose to vulnerable people.
 
It supports current plans in the UK to reduce the dose gap between

Disclaimer: No Business Standard Journalist was involved in creation of this content

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in